Abstract
Etanercept is an anti-TNF drug with marked efficacy in inflammatory arthritis. This review addresses dermatological side effects that have been encountered in our 85 patients on the drug for rheumatoid arthritis, and reviews other reported cutaneous adverse events. Injection site reactions are common and usually self-limiting. We and others have encountered patients with recall site reactions where the four rotated injection sites simultaneously develop a hypersensitivity reaction. In all cases, the rash has responded to antihistamines and the etanercept was thereby continued. Other injection site reactions include discoid lupus and cutaneous vasculitis that respond to cessation of treatment and appropriate therapy. Skin reactions more distant from the injection site are also reviewed, with erythema nodosum, widespread lupus rashes, infections and skin tumours summarised. A patient who developed a purpuric rash at the site of last injection with a drug induced worsening of thrombocytopaenia is described. Although the therapeutic advantages of etanercept outweigh the side effects, clinicians need to be aware of the adverse reactions of these drugs with their increasing use.
Keywords: Etanercept, injection site reactions, recall reactions, lupus, erythema nodosum, purpura
Current Drug Safety
Title: Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Volume: 1 Issue: 3
Author(s): Shyra Rajakulendran and Chris Deighton
Affiliation:
Keywords: Etanercept, injection site reactions, recall reactions, lupus, erythema nodosum, purpura
Abstract: Etanercept is an anti-TNF drug with marked efficacy in inflammatory arthritis. This review addresses dermatological side effects that have been encountered in our 85 patients on the drug for rheumatoid arthritis, and reviews other reported cutaneous adverse events. Injection site reactions are common and usually self-limiting. We and others have encountered patients with recall site reactions where the four rotated injection sites simultaneously develop a hypersensitivity reaction. In all cases, the rash has responded to antihistamines and the etanercept was thereby continued. Other injection site reactions include discoid lupus and cutaneous vasculitis that respond to cessation of treatment and appropriate therapy. Skin reactions more distant from the injection site are also reviewed, with erythema nodosum, widespread lupus rashes, infections and skin tumours summarised. A patient who developed a purpuric rash at the site of last injection with a drug induced worsening of thrombocytopaenia is described. Although the therapeutic advantages of etanercept outweigh the side effects, clinicians need to be aware of the adverse reactions of these drugs with their increasing use.
Export Options
About this article
Cite this article as:
Rajakulendran Shyra and Deighton Chris, Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934495
DOI https://dx.doi.org/10.2174/157488606777934495 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Dietary Approaches and Alternative Therapies for Rheumatoid Arthritis
Current Nutrition & Food Science First Autochthonous case of Emerged Zoonotic Cutaneous Leishmaniasis in Mazandaran Province, Northern Iran: kDNA-PCR Evidence Base
Infectious Disorders - Drug Targets Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics Selective Inhibitors of Human Neutrophil Proteinase 3
Current Pharmaceutical Design The Rationale and Development of New Drugs to Treat HIV Infection
Medicinal Chemistry Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Deciphering Tuberculous Meningitis: From Clinical Challenges to Novel Models and Pathogenic Pathways
Current Topics in Medicinal Chemistry Influence of Leptin on Immunity
Current Immunology Reviews (Discontinued) A Review on Response of Immune System in Spinal Cord Injury and Therapeutic Agents useful in Treatment
Current Pharmaceutical Biotechnology Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Multiple Roles of Annexin A2 in Post-Transcriptional Regulation of Gene Expressio
Current Protein & Peptide Science Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Gene Elements that Regulate Streptococcus pneumoniae Virulence and Immunity Evasion
Current Gene Therapy